Yuanda Pharmaceutical (00512) rose more than 5%. As of press release, it had risen 5.19% to HK$4.05, with a turnover of HK$31.9098 million.
The Zhitong Finance App learned that Yuanda Pharmaceutical (00512) rose by more than 5%. As of press release, it had risen 5.19% to HK$4.05, with a turnover of HK$31.9098 million.
According to the news, Yuanda Pharmaceutical recently announced its 2023 annual results. The company recorded annual revenue of about HK$10.53 billion, up 15.8% year on year after excluding exchange rate effects; gross profit of about HK$6.52 billion, up 15.3% year on year before exchanging exchange rate effects; net profit from normalization was about HK$2.04 billion, up 0.2% year on year after excluding exchange rate effects. The board of directors recommended a dividend of HK26 cents per share, with a total dividend of about HK$910 million. It has been distributed continuously for 6 years, with a cumulative dividend of approximately HK$2.8 billion.
During the year, the company achieved a total of 77 major milestones, including 42 innovative products; a total of 30 products were approved for listing, including 5 innovative products; the company added 17 core patents and 118 patent authorizations. Furthermore, as a core major product in Yuanda Pharmaceutical's many innovative nuclear drug product lines, the revenue of Yigantai Yttrium [90Y] microsphere injections achieved a growth rate of nearly 300% in 2023.